Abstract-We aimed to investigate the relationship of time-averaged on-treatment systolic blood pressure (SBP) with the risk of first stroke in the CSPPT (China Stroke Primary Prevention Trial). A post hoc analysis was conducted using data from 17 720 hypertensive adults without cardiovascular disease, diabetes mellitus, and renal function decline from the CSPPT, a randomized double-blind controlled trial. The primary outcome was first stroke. Over a median follow-up duration of 4.5 years, the association between averaged on-treatment SBP and risk for first stoke followed a U-shape curve, with increased risk above and below the reference range of 120 to 130 mm Hg. 
Several randomized trials support the use of blood pressure (BP)-lowering drugs to reduce the risk of cardiovascular disease (CVD). A meta-analysis of 61 prospective studies, including 1 million adults with no previous vascular disease at baseline who were subsequently followed for ≈14 years, showed a linear relationship between SBP and cardiovascular risk down to 115 mm Hg. 4 However, although the most appropriate targets for SBP lowering have long been debated in high-risk patients, [5] [6] [7] [8] such as those with diabetes mellitus or a history of CVD, or renal disease, few studies [9] [10] [11] have focused on optimal SBP levels in hypertensive adults without such diseases. According to the 2013 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension, an SBP goal of <140 mm Hg was recommended, primarily based on data from 3 trials with noted limitations. 12 As a result, the Eighth Joint National Committee recommended a goal of SBP <140 mm Hg in the general population both for those aged ≥60 years or <60 years, though this recommendation was merely based on evidence graded as Expert Opinion-Grade E. 13 Data from the CSPPT (China Stroke Primary Prevention Trial) 14 showed that during a median follow-up duration of 4.5 years, the combined use of enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke by 21% among hypertensive adults without a history of stroke or myocardial infarction (MI) in China. The mean SBP was highly comparable between the 2 treatment groups at baseline and during follow-up. This current post hoc analysis of the CSPPT aimed to investigate the relationship between time-averaged on-treatment SBP and the risk of first stroke in hypertensive adults with normal renal function and without CVD or diabetes mellitus.
Methods Participants
The methods and primary results of the CSPPT trial have been reported elsewhere.
14 Briefly, the CSPPT was a multicenter, randomized controlled trial conducted from May 19, 2008 , to August 24, 2013 , in 32 communities in the Jiangsu and Anhui provinces in China to test the hypothesis that therapy with enalapril and folic acid is more effective in reducing first stroke than that with enalapril alone among Chinese adults with hypertension. Eligible participants were men and women aged 45 to 75 years with hypertension, defined as seated resting SBP ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg at both the screening and recruitment visits, or who had previously taken antihypertensive medication. The major exclusion criteria included history of physician-diagnosed stroke, MI, heart failure, postcoronary revascularization, and congenital heart disease.
This study was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (Federal Wide Assurance number: FWA00001263). All participants gave written informed consent prior to data collection.
Intervention and Follow-Up
Eligible participants, stratified by methylenetetrahydrofolate reductase (MTHFR) C677T genotypes (CC, CT, or TT), were randomly assigned, in a 1:1 ratio, to 1 of 2 treatment groups: a daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid (single tablet combination; the enalapril-folic acid group) or a daily oral dose of 1 tablet containing 10 mg enalapril only (the enalapril only group). All study investigators and participants were blinded to the randomization procedure and the treatment assignments. During the trial period, concomitant use of other antihypertensive drugs (mainly calcium channel blockers or diuretics) was allowed, but not B vitamins. Participants were scheduled for follow-up every 3 months. At each follow-up visit, vital signs, study drug compliance, concomitant medication use, adverse events, and possible end point events were documented by trained research staff and physicians.
Seated BP measurements were obtained by trained research staff after the patients had been seated for 10 minutes by using a mercury manometer and using the standard method and appropriately sized cuffs. Triplicate measurements on the same arm were taken with at least 2 minutes between readings. The mean SBP and DBP of the 3 independent measures were used in the analyses.
Outcomes
The primary outcome was a first nonfatal or fatal stroke (ischemic or hemorrhagic), excluding subarachnoid hemorrhage and silent stroke. Secondary outcomes included a composite of cardiovascular events consisting of cardiovascular death, MI, and stroke and first ischemic stroke (fatal and nonfatal). All of the study outcomes were reviewed and adjudicated according to standard criteria by an independent End Point Adjudication Committee.
Statistical Analysis
Time-averaged on-treatment SBP was calculated for each participant using all of the post-baseline SBP results up to the last visit before the date of primary outcome or death or the end of follow-up in those patients without events. Participants with a history of diabetes mellitus or under treatment for diabetes mellitus at baseline were classified as having diabetes mellitus. Estimated glomerular filtration rate was calculated using the equation provided by the Chronic Kidney Disease Epidemiology Collaboration. 15 Baseline characteristics are presented as mean (continuous variables) or percentage (categorical variables) as appropriate, stratified by time-averaged on-treatment SBP categories (120, 120-130, 130-135, 135-140, and ≥140 mm Hg). Outcomes in various groups of on-treatment SBP were compared using the Kaplan-Meier method and log-rank test. Multivariable Cox proportional hazard regression models were used to evaluate the role of on-treatment SBP on the risk of outcomes, and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to evaluate the risks. Consistency of the results in various subgroups (sex, age, and study treatment groups) was also explored using Cox proportional hazard regression models.
A 2-tailed P<0.05 was considered to be statistically significant in all analyses. Empower(R) (www.empowerstats.com; X&Y solutions, Inc., Boston MA) and R software, version 3.1.2 (http://www.r-project.org) were used for all statistical analyses.
Results

Study Participants and Baseline Characteristics
The total sample of the CSPPT was 20 702. At baseline, 2288 participants with diabetes mellitus or with missing data on fasting glucose (n=361), 327 participants with estimated glomerular filtration rate <60 mL/min per 1.73 m 2 or with missing data on estimated glomerular filtration rate (n=5), and 1 participant without an SBP measurement during the follow-up period were excluded. A total of 17 720 participants constituted our final analysis set.
At baseline, 324, 3062, 3178, 3435, and 7720 participants had time-averaged on-treatment SBP <120 mm Hg, ≥120 and <130 mm Hg, ≥130 and <135 mm Hg, ≥135 and <140 mm Hg, and ≥140 mm Hg, respectively. Baseline characteristics of participants according to time-averaged on-treatment SBP categories (<120, 120-130, 130-135, 135-140, and ≥140 mm Hg) are summarized in Table 1 . Participants with lower on-treatment BP tended to have younger age, lower body mass index, higher folate levels, and lower serum fasting glucose, total cholesterol, triglycerides, creatinine, and homocysteine concentrations.
Time-Averaged On-Treatment SBP and Risk of Primary and Secondary Outcomes
The mean time-averaged on-treatment SBP levels were 116.7, 126.2, 132.6, 137.5, and 149.6 mm Hg, respectively, for participants with on-treatment SBP at <120, 120 to 130, 130 to 135, 135 to 140, and ≥140 mm Hg.
Over a median follow-up duration of 4.5 years, the association between time-averaged on-treatment SBP and risk of first stroke followed a U-shaped curve, with increased risk above and below the reference range of 120 to 130 mm Hg ( Figure 1 ; Figure S1 in the online-only Data Supplement). Compared with participants with time-averaged on-treatment SBP at 120 to 130 mm Hg (mean, 126.2 mm Hg), the risk of first stroke was not only increased in participants with SBP at 130 to 135 mm Hg (mean, 132.6 mm Hg; 1.5% versus 0.8%; HR, 1.63; 95% CI, 1.01-2.63) or 135 to 140 mm Hg (mean, 137.5 mm Hg; 1.9% versus 0.8%; HR, 1.85; 95% CI, 1.17-2.93), but also increased in participants with SBP <120 mm Hg (mean, 116.7 mm Hg; 3.1% versus 0.8%; HR, 4.37; 95% CI, 2.10-9.07). Similar results were observed for the composite cardiovascular events and ischemic stroke ( Table 2) .
In other words, even compared with those with usual control of SBP (130-140 mm Hg), participants with a tighter SBP control (120-130 mm Hg) were associated with lower first stroke risk. Compared with those with on-treatment SBP at 135 to 140 and 130 to 135 mm Hg, the risk of first stroke in participants with on-treatment SBP at 120 to 130 mm Hg was reduced by 46% (1.9% versus 0.8%; HR, 0.54; 95% CI, 0.34-0.86) and 39% (1.5% versus 0.8%; HR, 0.61; 95% CI, 0.38-0.99), respectively. Furthermore, compared with those with uncontrolled SBP (≥140 mm Hg), a significantly lower risk of first stoke was observed in those with usual control of SBP (versus 135-140 mm Hg; 4.4% versus 1.9%; HR, 0.48; 95% CI, 0.37-0.64; versus 130-135 mm Hg; 4.4% versus 1.5%; HR, 0.43; 95% CI, 0.31-0.58; Table S1 ). Moreover, only 0.7% of the participants used the lipid-lowering drugs 
Triglycerides, mmol/L 1.6 (0.9) 1.5 (0.8) at baseline. Excluding these participants did not substantially change the results (Table S2) . Stratified analyses were performed by sex, age (<60 versus ≥60 and <65 versus ≥65 years), and study treatment group. The lowest risk of first stroke was observed in participants with time-averaged on-treatment SBP at 120 to 130 mm Hg in all of the subgroups. There were no significant interactions in any of the subgroups (P>0.05 for all comparisons; Figure 2 ; Table S3 ).
Time-Averaged On-Treatment DBP and Risk of Primary and Secondary Outcomes
The mean time-averaged on-treatment DBP level was 75.3, 84.5, and 94.9 mm Hg, respectively, for participants with ontreatment DBP at <80, 80 to 90, and ≥90 mm Hg.
Compared with those with on-treatment DBP at <80 mm Hg, a significantly increased risk of first stroke was observed in those with DBP at 80 to 90 mm Hg (2.6% versus 1.6%; HR, 2.14; 95% CI, 1.65-2.77) or ≥90 mm Hg (5.4% versus 1.6%; HR, 5.55; 95% CI, 4.04-7.62). Similar results were observed for the composite cardiovascular events or ischemic stroke (Table 3) .
More importantly, a lower on-treatment DBP was associated with a higher on-treatment pulse pressure (Table S4) . However, we did not observe a U-shaped association between on-treatment DBP and risk of first stroke (Figure 1 ). There was no significant difference in the risk of first stroke between those with on-treatment DBP at 70 to 80 mm Hg and at <70 mm Hg (Table S4 ).
Discussion
The current analysis was the first study to investigate the relationship between time-averaged on-treatment SBP and the risk of first stroke in hypertensive adults with normal renal function and without CVD or diabetes mellitus. Our results suggest that a tight SBP control (120-130 mm Hg) was related to a lower risk of stroke, compared with usual control of SBP (135-140 or 130-135 mm Hg). Most importantly, an increased stroke risk was observed in those participants with a further reduction in SBP (<120 mm Hg). Furthermore, lower time-averaged on-treatment DBP was associated with a lower risk of stroke. Therefore, the increased stroke risk of those with on-treatment SBP <120 mm Hg could not be explained by the combined lowest time-averaged on-treatment DBP levels (76.1 mm Hg; Table 1) .
A recent meta-analysis 16 found that intensive BP-lowering treatment provided greater vascular protection did than standard regimens. However, after randomization, the mean SBP was 133 and 140 mm Hg, respectively, in the intensive BP-lowering treatment group and in the standard treatment group. In other words, most of the patients in the standard treatment group had uncontrolled SBP (≥140 mm Hg). The Cardio-Sis, 17 ACCORD (Action to Control Cardiovascular Risk in Diabetes), 18 and SPRINT (Systolic Blood Pressure Intervention Trial) 19 are 3 randomized trials designed to assess the efficacy of tight SBP control on cardiovascular outcomes, compared with usual SBP control (130-140 mm Hg). In the Cardio-Sis trial, 17 a total of 1111 nondiabetic patients aged ≥55 years with SBP of ≥150 mm Hg were randomly assigned to a target SBP of <140 mm Hg (usual control; n=553) or <130 mm Hg (tight control; n=558). The tight SBP control was associated with lower stroke or transient ischemic attack risk (HR, 0.44; 95% CI, 0.13-1.42). However, because the average SBP was 135.6 mm Hg in the usual control group and 131.9 mm Hg in the tight control group at the end of the study (2-year trial), the Cardio-Sis trial was not able to provide informative data on the supposed benefit of an SBP target <130 mm Hg. The ACCORD and SPRINT trials aimed to compare the benefits of treatment for SBP to a target of <120 mm Hg with treatment to a target of 130 to 140 mm Hg on hypertension-related complications. As compared with the usual SBP control (ACCORD: ≈130-135 mm Hg; SPRINT: ≈135-140 mm Hg), the tight SBP control resulted in lower rates of stroke (overall: HR, 0.75; 95% CI, 0.58-0.97; ACCORD: HR, 0.59; 95% CI, 0.39-0.89; SPRINT: HR, 0.89; 95% CI, 0.64-1.09). 18, 19 It is noteworthy that the number of patients with stroke in SPRINT was low with no significant difference between the 2 groups, the reason for which possibly being that SPRINT was stopped prematurely because of an expected significant difference in the soft end point heart failure (HR, 0.62; 95% CI, 0.45-0.84) because of the larger doses of diuretics throughout the treatment. However, although an average of 3 different antihypertensive drugs were used in the tight SBP control group, the average SBPs were 119.3 and 121.4 mm Hg, respectively, in the ACCORD and SPRINT studies. These results indicate that many of the participants did not reach the goal of an SBP of <120 mm Hg and instead had an SBP of 120 to 130 mm Hg even in the tight SBP control group. Furthermore, the BP measurement method used in SPRINT has resulted in lower BP values than those routinely obtained by research staff in the clinic, and the strict BP target of <120 mm Hg might actually be higher if using routine BP. 20 Consistently, even compared with those with usual control of SBP (130-135 or 135-140 mm Hg), those in the tighter SBP control group (120-130 mm Hg) significantly reduced their risk of first stroke in the CSPPT. In fact, even with a conservative BP goal of 140/90 mm Hg, the control rate of BP in hypertensive adults was only ≈50% and 9.4%, respectively, in the United States and China. 2, 21 Therefore, based on the results from ACCORD, SPRINT, and the findings from the post hoc analysis of the CSPPT, and in consideration of the current challenges associated with stricter SBP control, the treatment goal to lower SBP to 120 to 130 mm Hg (rather than <120 mm Hg) is more reasonable and accessible in a high-risk population and especially in subjects without CVD, diabetes mellitus, and renal function decline, like the participants included in this subanalysis of CSPPT.
Most importantly, the CSPPT first found that the risk of first stoke was significantly increased in participants with on-treatment SBP <120 mm Hg, compared with those with on-treatment SBP at 120 to 130 mm Hg. Consistently, in previous post hoc analyses of antihypertensive treatment trials, an SBP <120 mm Hg was also associated with an increased risk for cardiovascular death ( 24 Moreover, an SBP <120 mm Hg, compared with the standard treatment, was associated with significantly increased risks of serious adverse events, such as hypotension, syncope, electrolyte abnormality, or estimated glomerular filtration rate <30 mL/min per 1.73 m 2 , in ACCORD 18 and hypotension, acute kidney injury or acute renal failure, hypokalemia, or hyponatremia in SPRINT. 19 However, there was a rather low number of participants and especially a low number of stroke events (n=10) in the group with SBP <120 mm Hg. Therefore, in this light, our results can be viewed as hypothesis generating. Confirmation of our findings in a large-scale randomized trial is essential.
In fact, although the U-shaped phenomenon has been shown in several previous studies, some trial analyses have raised the point that the U shape applies largely to the coronary circulation but not to the cerebral circulation. [25] [26] [27] [28] The CSPPT provides further evidence that a U shape may also exist for first stroke. Furthermore, there has been speculation that the U-shaped effect observed in these trials may be because of a form of reverse causality, whereby the low BPs were actually because of the existing increased baseline cardiovascular risk or poor health. However, this seems unlikely in the CSPPT because only participants without stroke and major coronary heart disease were enrolled. Furthermore, participants with on-treatment SBP of <120 mm Hg had lower cardiovascular risk, including younger age, lower body mass index, and lower serum fasting glucose, total cholesterol, triglycerides, and creatinine levels. In addition, the U-shaped relationship between SBP and the risk of first stroke persisted even after controlling for baseline covariates. Further analysis of the ACCORD and SPRINT trials could provide more evidence about the risks and benefits associated with an on-treatment SBP of <120 mm Hg in high-risk populations.
As noted, the Eighth Joint National Committee recommended different SBP control goals for participants aged <60 and ≥60 years. 13 However, the lowest risk of first stroke was found in participants with on-treatment SBP at 120 to 130 mm Hg in all of the age subgroups (<60 versus ≥60 and <65 versus ≥65 years) in the CSPPT. Furthermore, the greater beneficial effect on the primary outcome (the first occurrence of MI, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes) was observed in the intensive BP control group (versus standard BP control group) among Model 1 was adjusted for age, sex, study centers, and study treatment groups. Model 2 was adjusted for age, sex, study centers, study treatment groups, MTHFR C677T polymorphism, body mass index, smoking, systolic and diastolic blood pressure, eGFR levels, fasting glucose, total cholesterol, highdensity lipoprotein cholesterol, triglycerides, folate, and homocysteine levels at baseline. CI indicates confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MTHFR, methylenetetrahydrofolate reductase; and SBP, systolic blood pressure.
participants aged ≥75 years (HR, 0.67; 95% CI, 0.51-0.86 versus <75 years, HR, 0.80; 95% CI, 0.54-1.00) in the SPRINT trial. 19 These results consistently suggest that older participants with hypertension may also benefit from stricter SBP control.
The CSPPT was conducted in Chinese adults without preexisting stroke or MI. Our findings in patients with SBP <120 mm Hg and low cardiovascular risk extend on similar previous results. This study also had several limitations. First, this was a post hoc analysis of a randomized clinical trial that did not randomize participants to different on-treatment SBP groups. This could have led to possible confounding because of differences between the SBP groups both at baseline and during follow-up. Although we adjusted our analysis for baseline confounders, we cannot exclude the possibility that unmeasured confounding may explain some of our findings. Second, just as in the Cardio-Sis study, 17 we did not measure glycosylated hemoglobin A1c or perform glucose tolerance tests at baseline. Third, the CSPPT was underpowered for assessing the association between on-treatment BP and the risk of first hemorrhagic stroke or nonstroke events in the composite of cardiovascular events. Fourth, a time-averaged on-treatment BP of 120 to 130 mm Hg or <120 mm Hg in our current study is not exactly the same as BP management with a strict goal of SBP control of 120 to 130 mm Hg or <120 mm Hg. Furthermore, our current study could not evaluate whether the effect of having a decreasing average over time in the interval 120 to 130 mm Hg was more important than consistently being at target 120 to 130 mm Hg. The time-averaged on-treatment BP reflects the effect of long-term control of the on-treatment office BP. The major problem with timeaveraged on-treatment BP is the difficulty in implementing it shortly after the start of treatment. It will take some time to have a good idea of a patient's time-averaged on-treatment BP in a prospective context. Furthermore, we cannot neglect the modifying effect of visit-to-visit BP variability. In the current study, SBP variability, which was defined as the standard deviation of all post baseline SBP results up to the last visit before the date of primary outcome or death or the end of follow-up in those patients without events, was also significantly associated with the risk of stroke (per SD increase of the SBP SD: HR, 1.64; 95% CI, 1.27-2.13). However, further adjustment for BP variability did not substantially change our results (Table S5 ). The other important limitation is that we could not evaluate the effect of 24-hour ambulatory BP in the present study. Overall, the CSPPT was not specifically designed to determine the office BP goal for the prevention of CVD. Our current results merely indicated the possible beneficial or detrimental effect when the long-term mean on-treatment BP was reduced to a certain level. Therefore, confirmation of our findings in a large-scale clinical trial of participants who are randomized to different on-treatment SBP targets is essential.
Perspectives
In conclusion, a lower SBP goal of 120 to 130 mm Hg, as compared with the target SBP of 130 to 140 mm Hg or <120 mm Hg, resulted in the lowest risk of first stroke among adults with hypertension in China without a history of stroke or MI, diabetes mellitus, and renal function decline. Our data provide new evidence for setting a lower SBP goal than is currently recommended in general hypertensive patients for the primary prevention of stroke. This finding may have great implications for other hypertensive populations living in regions, such as China, where there is a higher risk of stroke than MI. Model 1 was adjusted for age, sex, study centers, and study treatment groups. Model 2 was adjusted for age, sex, study centers, study treatment groups, MTHFR C677T polymorphism, body mass index, smoking, systolic and diastolic blood pressure, eGFR levels, fasting glucose, total cholesterol, highdensity lipoprotein cholesterol, triglycerides, folate, and homocysteine levels at baseline. CI indicates confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MTHFR, methylenetetrahydrofolate reductase; and DBP, diastolic blood pressure.
